Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL645055 | 0.98 | NISCH (0.39) | NISCHALDH1A1HSD17B10HIF1AHPGD | |
| Hydrochloric Acid SCHEMBL6448208 | 0.98 | NISCH (0.39) | NISCHALDH1A1HSD17B10HIF1AHPGD | |
| SCHEMBL1672648 | 0.82 | ALDH1A1 (0.43) | ALDH1A1HSD17B10HIF1AHPGDTSHR | |
| SCHEMBL13183866 | 0.74 | MAPT (0.46) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL774738 | 0.74 | ESR1 (0.42) | ALDH1A1HSD17B10HPGDTSHRL3MBTL1 | |
| SCHEMBL2065826 | 0.73 | KIF11 (0.46) | ALDH1A1HSD17B10HPGDTSHRMAPK1 | |
| SCHEMBL13183802 | 0.72 | AR (0.40) | KDM4EMEN1MAPTKMT2ACYP2A6 | |
| SCHEMBL16796324 | 0.71 | CYP3A4 (0.39) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL28312968 | 0.70 | CYP1A2 (0.41) | ALDH1A1HSD17B10HPGDTSHRL3MBTL1 | |
| SCHEMBL21725429 | 0.69 | CYP11B1 (0.41) | NISCHALDH1A1HSD17B10HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011130677-A1 | INHIBITORS OF CANCER STEM CELLS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-10-20 | — | — | WO | claimed |
| US-20250074917-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | PURDUE RESEARCH FOUNDATION | 2025-03-06 | — | — | US | disclosed |
| CN-119497715-A | Preparation and application of 7-aza-indeno isoquinoline | 珀杜研究基金会 | 2025-02-21 | — | — | CN | disclosed |
| EP-4507736-A1 | COMBINATION THERAPY FOR TREATING TROP-2 EXPRESSING CANCERS | GILEAD SCIENCES, INC. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20240287089-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | PURDUE RESEARCH FOUNDATION (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2024097812-A1 | THERAPY FOR TREATING BLADDER CANCER | GILEAD SCIENCES, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023215238-A1 | PREPARATION AND USES OF 7-AZAINDENOISOQUINOLINES | PURDUE RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023201267-A1 | COMBINATION THERAPY FOR TREATING TROP-2 EXPRESSING CANCERS | GILEAD SCIENCES, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| EP-3480187-B1 | METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES | UNIV NAT TAIWAN NORMAL (TW) | 2023-10-04 | — | — | EP | disclosed |
| US-20230219895-A1 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | SHENZHEN XUHUA BIOTECH CO. LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20030096833-A1 | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2003-05-22 | — | — | US | disclosed |
| US-20030096833-A1 | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2003-05-22 | — | — | US | disclosed |
| US-20030096833-A1 | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2003-05-22 | — | — | US | disclosed |
| WO-2003020700-A2 | SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020700-A2 | SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002040653-A2 | CHRYSTAL COMPOSITIONS COMPRISING TOPOISOMERASE I | EMERALD BIOSTRUCTURES, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| US-5597831-A | 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents | VUFB A.S (CS) | 1997-01-28 | — | — | US | disclosed |
| EP-0643699-B1 | 6-(2-HYDROXYETHYLAMINOALKYL)-5,11-DIOXO-5,6-DIHYDRO-11H- INDENO[1,2-C]ISOQUINOLINES AND THEIR USE AS ANTINEOPLASTIC AGENTS | VUFB AS (CZ) | 1996-10-23 | — | — | EP | disclosed |
| EP-0643699-A1 | 6((2-HYDROXYETHYL)AMINO ALKYL)-5,11-DIOXO-5,6-DIHYDRO-11-H-INDENO(1,2-C)ISOQUINOLINE AND THEIR USE AS ANTINEOPLASTIC AGENTS. | VYZK USTAV FARM BIOCHEM SP (CS) | 1995-03-22 | — | — | EP | disclosed |
| WO-1993005023-A1 | 6((2-HYDROXYETHYL)AMINO ALKYL)-5,11-DIOXO-5,6-DIHYDRO-11-H-INDENO(1,2-C)ISOQUINOLINE AND THEIR USE AS ANTINEOPLASTIC AGENTS | VYZKUMNY USTAV PRO FARMACII A BIOCHEMII, S.P. (CS) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074917-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | MYC, MYCBP, DNMT1 | NISCH 2201/4885ALDH1A1 4307/4885HSD17B10 4500/4885 |
| US-20030096833-A1 | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof | UGT1A1, XPO1, IPO7 | NISCH 56/4885ALDH1A1 956/4885HSD17B10 922/4885 |
| US-20230219895-A1 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | TDP1, TOP1, TOP2A | NISCH 3468/4885ALDH1A1 663/4885HSD17B10 1687/4885 |
| US-20240287089-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | MYC, MYCBP, DNMT1 | NISCH 2201/4885ALDH1A1 4307/4885HSD17B10 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.